Biomarin Pharmaceutical Inc. (BMRN) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
BioMarin Pharmaceutical Inc. (BMRN) is running a late stage trial that compares its new drug BMN 333 with Vosoritide in children with achondroplasia. The official name is a multicenter Phase 2/3 study that looks at both how well the drug works and how safe it is, and the goal is to show that BMN 333 can offer a better or more convenient option in this rare growth disorder.
BMN 333 is a weekly injection designed to improve growth and bone development in children with achondroplasia. It is tested directly against Vosoritide, sold as Voxzogo, which is a daily injection already used for the same condition.
The study is interventional and randomized, so children are assigned by chance to either BMN 333 or Vosoritide. It uses a parallel design and single masking, meaning the person who measures the results does not know which treatment a child is on, and the main aim is to treat the condition rather than just observe it.
In Phase 2, children receive low, medium, or high doses of BMN 333 or Vosoritide to find the best dosing level. Phase 3 then uses the chosen BMN 333 dose versus Vosoritide to confirm benefits on growth and safety over a longer period.
The trial is listed as recruiting, which signals it is still early but active. It was first submitted on February 11, 2026, and the last update was filed on April 20, 2026, which matters because recent updates often drive investor attention and suggest steady operational progress.
For investors, this trial matters because it positions BMN 333 directly against Voxzogo, a key product in pediatric achondroplasia. If BMN 333 shows similar or better growth outcomes with less frequent dosing, BMRN could defend or grow its share in a niche market with high pricing power.
The design as a seamless Phase 2/3 program may shorten time to market if results are strong, which can support a higher valuation for BMRN’s rare disease pipeline. However, the head to head setup also raises downside risk because underperformance versus Vosoritide could weigh on sentiment and compress future revenue expectations.
Competitors in rare disease and growth disorder drugs will watch closely, since success could strengthen BioMarin’s position in skeletal dysplasia and limit room for new entrants. Investors should expect interim news to move the stock well before final readouts, especially around dose selection and any early safety or efficacy signals.
This study is currently ongoing and has been recently updated, and investors can find further details and status changes on the ClinicalTrials.gov portal.
To learn more about BMRN’s potential, visit the Biomarin Pharmaceutical Inc. drug pipeline page.